MX356271B - Composiciones de alquilglicósido para administracion de farmacos. - Google Patents

Composiciones de alquilglicósido para administracion de farmacos.

Info

Publication number
MX356271B
MX356271B MX2011006790A MX2011006790A MX356271B MX 356271 B MX356271 B MX 356271B MX 2011006790 A MX2011006790 A MX 2011006790A MX 2011006790 A MX2011006790 A MX 2011006790A MX 356271 B MX356271 B MX 356271B
Authority
MX
Mexico
Prior art keywords
compositions
drug administration
methods
alkylglycoside
bioavailability
Prior art date
Application number
MX2011006790A
Other languages
English (en)
Other versions
MX2011006790A (es
Inventor
T Maggio Edward
Original Assignee
Aegis Therapeutics Llc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegis Therapeutics Llc Star filed Critical Aegis Therapeutics Llc Star
Publication of MX2011006790A publication Critical patent/MX2011006790A/es
Publication of MX356271B publication Critical patent/MX356271B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona composiciones y métodos para incrementar la bio-disponibilidadd de agentes terapéuticos en un sujeto, así como composiciones y métodos para proporcionar alivio al dolor de migraña. Las composiciones incluyen por lo menos un alquil glicósido y por lo menos un agente terapéutico, tal como un agonista del receptor de 5-HT, en donde el alquil glicósido tiene una longitud de cadena alquilo de alrededor de 10 a alrededor de 16 átomos de carbono.
MX2011006790A 2008-12-22 2009-12-22 Composiciones de alquilglicósido para administracion de farmacos. MX356271B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/341,696 US8268791B2 (en) 2004-08-25 2008-12-22 Alkylglycoside compositions for drug administration
PCT/US2009/069326 WO2010075465A1 (en) 2008-12-22 2009-12-22 Compositions for drug administration

Publications (2)

Publication Number Publication Date
MX2011006790A MX2011006790A (es) 2011-09-27
MX356271B true MX356271B (es) 2018-05-21

Family

ID=42288137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006790A MX356271B (es) 2008-12-22 2009-12-22 Composiciones de alquilglicósido para administracion de farmacos.

Country Status (14)

Country Link
US (1) US8268791B2 (es)
EP (1) EP2381773B1 (es)
JP (2) JP5752048B2 (es)
KR (1) KR101719008B1 (es)
CN (1) CN102325450B (es)
AU (1) AU2009329952B2 (es)
BR (1) BRPI0923403B1 (es)
CA (1) CA2748268C (es)
DK (1) DK2381773T3 (es)
ES (1) ES2667248T3 (es)
MX (1) MX356271B (es)
NZ (1) NZ593782A (es)
RU (1) RU2554814C2 (es)
WO (1) WO2010075465A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DK2020990T3 (da) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
EP2813144A1 (en) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
JP2010526822A (ja) * 2007-05-07 2010-08-05 クエスター ファーマシューティカルズ，インク． ベンゾジアゼピン類の経鼻投与
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
JP5845183B2 (ja) * 2009-09-25 2016-01-20 ドクター・レディーズ・ラボラトリーズ・リミテッド トリプタン化合物を含む製剤
BR112012007087A2 (pt) * 2009-09-25 2020-08-11 Dr. Reddy's Laboratoires Limited composições farmacêuticas compreendendo compostos triptano e uso das mesmas para a preparação de um medicamento para tratar condições associadas à dor cefálica
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
EP2480197B1 (en) 2009-09-25 2015-11-11 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
WO2011037623A1 (en) * 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120270778A1 (en) * 2009-12-18 2012-10-25 Aegis Therapeutics Llc Compositions and Methods for Non-Invasive Treatment of Chronic Complications of Diabetes
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
US20150132344A1 (en) * 2010-11-18 2015-05-14 Universite De Montreal Oral Leptin Formulations and Uses Thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP4085899A1 (en) 2011-06-14 2022-11-09 Neurelis, Inc. Administration of benzodiazepine
CA2855545A1 (en) * 2011-11-18 2013-05-23 Universite De Montreal Oral leptin formulations and uses thereof
CN104619369B (zh) * 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
WO2015032981A1 (en) * 2013-09-09 2015-03-12 Lek Pharmaceuticals D.D. Erythropoietin conjugates having oral bioavailability
EP3052604B1 (en) * 2013-09-30 2023-05-31 Enza Biotech AB Use of alkylglycosides surfactants
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA52253A (fr) 2015-02-17 2021-02-17 Lilly Co Eli Formulation de poudre nasale pour le traitement de l'hypoglycémie
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
WO2017004501A1 (en) 2015-07-02 2017-01-05 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
EP3368159A1 (en) * 2015-10-28 2018-09-05 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions for rizatriptan
PT3369429T (pt) 2015-10-30 2020-02-20 Teijin Pharma Ltd Composição farmacêutica para administração na mucosa nasal
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN109789122A (zh) * 2016-06-24 2019-05-21 欧邦特制药公司 用于治疗酒精使用病症的组合物、装置和方法
EP3541386A4 (en) * 2016-11-18 2020-05-27 Opiant Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATING OPIOID OVERDOSE
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
CN109310777B (zh) * 2017-02-09 2021-07-30 积水化学工业株式会社 芯壳结构体、制剂、外用药、胶带剂以及化妆品
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
US20220096438A1 (en) 2018-09-07 2022-03-31 Upsher-Smith Laboratories, Llc Methods of treating migraine
PH12021551465A1 (en) * 2018-12-20 2022-04-11 Aegis Therapeutics Llc Compositions, devices, and methods for the treatment of overdose and reward-based disorders
BR112021015467A2 (pt) * 2019-02-06 2021-10-05 Axsome Therapeutics, Inc. Composições farmacêuticas compreendendo meloxicam
CN114007617A (zh) * 2019-05-31 2022-02-01 葡瑞慕生物技术有限公司 用于经黏膜给药药物活性成分的单位剂型
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物
AU2021385052A1 (en) * 2020-11-19 2023-06-01 Pfizer Ireland Pharmaceuticals Compositions for improved delivery of cgrp inhibitors
WO2023014906A1 (en) 2021-08-04 2023-02-09 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
WO2024209050A1 (en) 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance
CN118924882A (zh) * 2023-05-10 2024-11-12 上海仁会生物制药股份有限公司 药物组合物及其用途、提高药物组合物贮存稳定性的方法
US12005077B1 (en) * 2023-09-28 2024-06-11 Terry Earl Brady Broad-spectrum antimicrobial, biocompatible and preservative-free functionalized fullerenes ophthalmic solution with reactive oxygen species scavenging and advanced targeting, penetration, and hydration

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US411210A (en) 1889-09-17 Water-wheel
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3547828A (en) 1968-09-03 1970-12-15 Rohm & Haas Alkyl oligosaccharides and their mixtures with alkyl glucosides and alkanols
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
DE2148279A1 (de) 1970-09-30 1972-04-06 Unilever N V , Rotterdam (Nieder lande) Geruststoffe fur Detergensmittel
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4036228A (en) 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4130709A (en) 1977-12-08 1978-12-19 Eli Lilly And Company Pleuromutilin glycoside derivatives
JPS57128634A (en) 1981-02-03 1982-08-10 Eisai Co Ltd Elastase-containing compound increasing absorption
US4440675A (en) 1981-08-18 1984-04-03 Meloy Laboratories, Inc. Human immune interferon
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
DE3444958A1 (de) 1984-12-10 1986-06-12 Henkel KGaA, 4000 Düsseldorf Verwendung von alkylglykosiden als potenzierungsmittel in antiseptischen mitteln sowie desinfektions- und reinigungsmittel mit verstaerkter bakterizider wirkung
DK17685D0 (da) 1985-01-14 1985-01-14 Hans Goeran Magnusson Glycosidderivater
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5550220A (en) 1987-05-13 1996-08-27 Curtice-Burns, Inc. Alkyl glycoside fatty acid polyester fat substitute food compositions and process to produce the same
US4938931A (en) 1987-05-26 1990-07-03 Hoechst Celanese Corporation Microporous membrane trickle bed reactor
US4921838A (en) 1987-06-16 1990-05-01 Trustees Of Boston University Angiogenic and blood perfusion inducing properties of amphiphilic compounds
WO1990005535A1 (fr) 1988-11-14 1990-05-31 Otsuka Pharmaceutical Co., Ltd. Preparation a base d'interferon pour administration nasale
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5122187A (en) 1989-06-22 1992-06-16 Xerox Corporation Hot melt ink compositions
US5198420A (en) 1989-10-02 1993-03-30 The General Hospital Corporation Use of mullerian inhibiting substance and its agonists and antagonists in the treatment of respiratory distress syndrome
US5369095A (en) 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
AU638146B2 (en) 1990-06-27 1993-06-17 Dainippon Ink And Chemicals Inc. Alkylated oligosaccharides and acetyl derivatives of the same
US5288707A (en) 1990-08-13 1994-02-22 Sandoz Ltd. Borolysine peptidomimetics
EP0513813B1 (en) 1991-05-16 1996-10-09 Kao Corporation Alkyl glycoside aqueous solution stable to microbial activity
US5552534A (en) 1991-08-22 1996-09-03 The Trustees Of The University Of Pennsylvania Non-Peptide peptidomimetics
US5317010A (en) 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5236707A (en) 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
US5550251A (en) 1991-12-12 1996-08-27 The Trustees Of The University Of Pennsylvania Alicyclic peptidomimetics
US5308531A (en) 1992-08-31 1994-05-03 Henkel Corporation Pine-oil containing hard surface cleaning composition
WO1994005262A1 (en) 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
WO1994020116A1 (en) 1993-03-10 1994-09-15 University Of Alabama Research Foundation Artificial primers for glycogen synthesis
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5510264A (en) 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
ES2171469T3 (es) 1993-10-21 2002-09-16 Hisamitsu Pharmaceutical Co Composicion administrada por via nasal y preparacion que la contiene.
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5955425A (en) 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
SE9404196D0 (sv) 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
EE9700138A (et) 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
SE9404468D0 (sv) 1994-12-22 1994-12-22 Astra Ab Powder formulations
US20030118594A1 (en) 1995-06-07 2003-06-26 Bishwajit Nag Stable formulations of mhc-peptide complexes
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US20050004049A1 (en) 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AU731909B2 (en) 1997-07-01 2001-04-05 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
ITMI981528A1 (it) 1998-07-03 2000-01-03 Recordati Ind Chimica E Farma Formulazioni topiche di aciclovir
FR2781152B1 (fr) 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US6495498B2 (en) 1999-05-27 2002-12-17 Johnson & Johnson Consumer Companies, Inc. Detergent compositions with enhanced depositing, conditioning and softness capabilities
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CA2393688A1 (en) 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US20030118547A1 (en) 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
US6610271B2 (en) 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040147473A1 (en) 2000-11-10 2004-07-29 Warrell Raymond P. Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
MXPA03004883A (es) 2000-12-01 2004-05-04 Battelle Memorial Institute Metodo para la estabilizacion de biomoleculas (por ejemplo, insulina) en formulaciones liquidas.
US6551578B2 (en) 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
EP2221376B1 (en) 2001-06-21 2012-11-21 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
EP1511509B1 (en) 2002-06-07 2007-10-10 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US20060106227A1 (en) 2002-06-13 2006-05-18 Dr Reddy's Laboratories Limited 3-'2-(Dimethylamino) ethyl!-n-methyl-1h-indole-5-methanesulfonamide and the succinate thereof
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
AU2003296413A1 (en) 2002-09-16 2004-04-30 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
GB0226076D0 (en) 2002-11-08 2002-12-18 Rp Scherer Technologies Inc Improved formulations containing substituted imidazole derivatives
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2004093917A2 (en) * 2003-04-22 2004-11-04 Nastech Pharmaceutical Company Inc. Intranasal administration of triptans
US20040258663A1 (en) 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
EP1631308B1 (en) 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
WO2005018565A2 (en) * 2003-08-21 2005-03-03 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
DE60322727D1 (de) 2003-12-15 2008-09-18 Phasys Gmbh M Rückgefaltetes Membranprotein in monodisperser Form
US20060074025A1 (en) 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
RU2006143544A (ru) 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US20090047347A1 (en) 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20060046969A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
CN106137952B (zh) 2004-11-12 2020-11-17 诺和诺德公司 促胰岛素肽的稳定制剂
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US7390788B2 (en) 2005-06-23 2008-06-24 Pert Candace B Peptide pharmaceutical compositions
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
KR101168674B1 (ko) * 2007-09-21 2012-07-25 생-고벵 아브라시프 연마제품용 메틸올멜라민

Also Published As

Publication number Publication date
RU2011130526A (ru) 2013-01-27
ES2667248T3 (es) 2018-05-10
JP2012513412A (ja) 2012-06-14
CA2748268A1 (en) 2010-07-01
AU2009329952B2 (en) 2014-01-09
EP2381773A4 (en) 2012-12-12
HK1164059A1 (en) 2012-09-21
RU2554814C2 (ru) 2015-06-27
US8268791B2 (en) 2012-09-18
BRPI0923403B1 (pt) 2022-02-08
MX2011006790A (es) 2011-09-27
US20090163447A1 (en) 2009-06-25
AU2009329952A1 (en) 2011-07-21
EP2381773A1 (en) 2011-11-02
CN102325450A (zh) 2012-01-18
CA2748268C (en) 2018-05-15
EP2381773B1 (en) 2018-02-14
JP5752048B2 (ja) 2015-07-22
KR20110099049A (ko) 2011-09-05
BRPI0923403A2 (pt) 2020-08-11
JP2015108008A (ja) 2015-06-11
NZ593782A (en) 2012-11-30
CN102325450B (zh) 2015-06-17
KR101719008B1 (ko) 2017-03-22
WO2010075465A1 (en) 2010-07-01
DK2381773T3 (en) 2018-05-28

Similar Documents

Publication Publication Date Title
MX356271B (es) Composiciones de alquilglicósido para administracion de farmacos.
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
MX2010006241A (es) Derivados de aminotriazol como agonistas de alx.
UA102681C2 (ru) Тризамещенные 1,2, 4-триазолы как модуляторы никотиновых ацетилхолиновых рецепторов
TW200640867A (en) Pyridine-3-carboxamide derivatives as CB1 inverse agonists
WO2012054500A3 (en) Compositions for drug administration
MX341197B (es) Compuestos de isoindol 5 - sustituidos.
NZ608673A (en) Therapeutic use of a tlr agonist and combination therapy
CY1108690T1 (el) Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων
MX2012004848A (es) Compuestos heterociclicos triciclicos.
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
JO3078B1 (ar) مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
NZ590650A (en) Buprenorphine analogs
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
JO3019B1 (ar) ثلاثي مستبدل 4،2،1-ثلاثي زولات
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
MY178894A (en) Therapeutic compositions containing macitentan
MX2010009462A (es) Derivados de indazol.
IN2012DN03042A (es)
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
UA83868C2 (ru) Производные бензимидазолона и хиназолинона в качестве агонистов человеческих рецепторов orl1
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
MY152685A (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
UA98472C2 (ru) Применение агониста рецептора epo человека для лечения интолерантности к глюкозе

Legal Events

Date Code Title Description
FG Grant or registration